EUVIMEDEUVIMED entdecken
Crossref

Single-Arm Combined Phase I/II Study Evaluating Limb Cryocompression to Prevent Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Taxane-Based Chemotherapy

Einarmige Phase-I/II-Studie zu einer kombinierten Extremitäten-Kryokompression zur Vorbeugung einer chemotherapieinduzierten peripheren Neuropathie bei Taxan-basierter Chemotherapie

Rachel S.J. Wong, Aishwarya Bandla, Yang En Yee, Wei Yen Ng, Yi Lin Chen, Yi Qing Tey, Jonathan Binder, Gayathri Kopattil, Samuel Guan Wei Ow, Lee Xin Wei Matilda, Siew Eng Lim, Seri Sastika und 14 weitere

JCO Oncology Advances · 2026-10 · 3 (4)

DOI: 10.1200/oa-26-00104 ↗

Auf einen Blick

In einer einarmigen Phase-I/II-Studie war Extremitäten-Kryokompression sicher und gut verträglich. Klinisch signifikante CIPN trat bei einem kleinen Teil der Patient:innen auf.

Fragestellung

Wirkt eine limb cryocompression zur Vorbeugung einer chemotherapieinduzierten peripheren Neuropathie bei Taxan-basierter Chemotherapie sicher und wirksam?

Methode

Prospektive einarmige Phase-I/II-Studie an 3 Zentren in Singapur; Kryokompression 30 Minuten vor, während und 30 Minuten nach Taxan-Infusion; Bewertung von Sicherheit, Verträglichkeit und CIPN.

Ergebnisse

150 Patient:innen eingeschlossen, 146 auswertbar. Verträglichkeit 84,2 %; 123 beendeten alle Zyklen. CTCAE-G1-CIPN 22,8 %, G2 1,6 %, keine G3/4; klinisch signifikante patientenberichtete CIPN 13,9 % nach 12 Wochen und 13,1 % nach 24 Wochen.

Schlussfolgerung der Autor:innen

Limb cryocompression ist sicher, gut verträglich und mit niedrigen Raten klinisch signifikanter CIPN bei Patient:innen unter Taxan-basierter Chemotherapie verbunden.

Kernaussagen

  • 84,2 % Verträglichkeit; 123 beendeten alle Kryokompressionszyklen
  • Keine CTCAE-G3/4-CIPN bei Behandlungsende
  • Klinisch signifikante patientenberichtete CIPN: 13,9 % und 13,1 %

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-10. Verfasst von Rachel S.J. Wong und 25 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben.

Auf einen BlickAbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity of taxane-based chemotherapy with no established preventive strategy. We evaluated the safety, tolerability, and efficacy of a novel limb cryocompression device in reducing CIPN.

Methods

In this prospective single-arm phase I/II study conducted at three sites in Singapore, patients with cancer scheduled for taxane-based chemotherapy received limb cryocompression (11°C; cyclic compression 5-15 mm Hg), starting 30 minutes before, during, and 30 minutes after taxane infusion. Primary end points included safety, tolerability, and clinically significant CIPN. CIPN was assessed by physician-graded Common Terminology Criteria for Adverse Events (CTCAE) and the patient-reported European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN 20-item scale (EORTC QLQ-CIPN20). A ≥3-point increase in the EORTC QLQ-CIPN20 sensory subscale defined clinically significant patient-reported CIPN. Taxane dose modifications attributable to CIPN were recorded.

Results

A total of 150 patients were enrolled (median age 52 years; 96.6% female; 89.0% breast cancer). Taxane regimens included paclitaxel (71.2%), docetaxel (28.1%), and nab-paclitaxel (0.68%); 44.5% received concurrent scalp cooling. A total of 146 patients were evaluable as four patients withdrew before commencing cryocompression. Tolerability was 84.2%; 123 patients completed all cryocompression cycles without premature termination. Fifteen patients (10.3%) withdrew because of cold intolerance. At treatment completion, 22.8% had CTCAE G1 CIPN and 1.6% had G2 CIPN; none developed G3/4 CIPN. Clinically significant patient-reported sensory CIPN occurred in 13.9% at 12 weeks and 13.1% at 24 weeks, and 5.7% required taxane dose modification because of CIPN.

Conclusion

Limb cryocompression is safe, well-tolerated, and associated with low rates of clinically significant CIPN in patients receiving taxane-based chemotherapy. A multicenter randomized controlled trial is ongoing to validate these findings (SWOG S2205 ICE COMPRESS; ClinicalTrials.gov identifier: NCT05642611 ).

Zitieren

APA

Wong, R. S., Bandla, A., Yee, Y. E., Ng, W. Y., Chen, Y. L., Tey, Y. Q., Binder, J., Kopattil, G., Ow, S. G. W., Matilda, L. X. W., Lim, S. E., Sastika, S., Lee, Y. M., Foo, P. L., Mustadi, H., Goh, R. Y., Ang, W. W., Tan, D. C., Burke, P., …, & Sundar, R. (2026). Single-Arm Combined Phase I/II Study Evaluating Limb Cryocompression to Prevent Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Taxane-Based Chemotherapy. JCO Oncology Advances, 3(4). https://doi.org/10.1200/oa-26-00104

Vancouver

Wong RS, Bandla A, Yee YE, Ng WY, Chen YL, Tey YQ, et al. Single-Arm Combined Phase I/II Study Evaluating Limb Cryocompression to Prevent Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Taxane-Based Chemotherapy. JCO Oncology Advances. 2026;3(4). doi:10.1200/oa-26-00104

BibTeX
@article{Wong2026,
  author = {Wong, Rachel S.J. and Bandla, Aishwarya and Yee, Yang En and Ng, Wei Yen and Chen, Yi Lin and Tey, Yi Qing and Binder, Jonathan and Kopattil, Gayathri and Ow, Samuel Guan Wei and Matilda, Lee Xin Wei and Lim, Siew Eng and Sastika, Seri and Lee, Yee Mei and Foo, Pei Ling and Mustadi, Haryani and Goh, Rosadhel Y.H. and Ang, Wee Wee and Tan, Doreen C.C. and Burke, Patrick and Sheldrake, Alexandra and Paxman, Richard and Choo, Su Pin and Chia, John and Lee, Soo Chin and Lim, Joline S.J. and Sundar, Raghav},
  title = {Single-Arm Combined Phase I/II Study Evaluating Limb Cryocompression to Prevent Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Taxane-Based Chemotherapy},
  journal = {JCO Oncology Advances},
  year = {2026},
  volume = {3},
  number = {4},
  doi = {10.1200/oa-26-00104}
}
Kostenlos starten →